类风湿关节炎自身抗原与抗原特异性耐受免疫治疗的前景
自身免疫病包括类风湿关节炎因免疫自身耐受受损而持续存在,现有非特异性免疫抑制治疗易感染且极少治愈。早期临床试验提示免疫治疗可能延长缓解甚至预防疾病进展,调控耐受是类风湿关节炎有前景的治疗方向。
要点
- 类风湿关节炎因免疫自身耐受受损而发病并持续,现有治疗极少实现无药缓解。
- 非特异性免疫抑制增加感染易感性且极少治愈,亟需抗原特异性策略。
- 早期临床试验提示免疫治疗可能延长缓解并预防疾病进展。
核心结论
- 调控自身抗原特异性免疫耐受是类风湿关节炎有前景的治疗方向,早期临床试验提示其可能延长缓解并预防疾病进展。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 类风湿关节炎因免疫自身耐受受损而发病并持续,诊断后患者极少达到无药缓解。
- 通过基因分型、抗体检测和症状可识别高危个体,但类风湿关节炎尚不能被成功预防。
- 当前非特异性免疫或炎症抑制治疗增加感染易感性且极少治愈。
- 早期临床试验提示免疫治疗可能延长缓解持续时间甚至预防疾病进展。
临床怎么用
- 临床可关注抗原特异性耐受免疫治疗作为延长缓解和预防疾病进展的潜在策略。
局限性
- 原文未报告综述的检索范围与纳入标准。
- 支持免疫治疗获益的证据来自早期临床试验,尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune diseases, including rheumatoid arthritis, develop and persist due to impaired immune self-tolerance, which has evolved to regulate inflammatory responses to injury or infection. After diagnosis, patients rarely achieve drug-free remission, and although at-risk individuals can be identified with genotyping, antibody tests, and symptoms, rheumatoid arthritis cannot yet be successfully prevented. Precision medicine is increasingly offering solutions to diseases that were previously considered to be incurable, and immunotherapy has begun to achieve this aim in cancer. Comparatively, modulating autoantigen-specific immune responses with immunotherapy for the cure of autoimmune diseases is at a relatively immature stage. Current treatments using non-specific immune or inflammatory suppression increase susceptibility to infection, and are rarely curative. However, early stage clinical trials suggesting that immunotherapy might allow extended duration of remission and even prevention of progression to disease suggest modulating tolerance in rheumatoid arthritis could be a promising opportunity for therapy.
引用
- Nel HJ, Malmström V, Wraith DC, et al. Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy. Lancet Rheumatol. 2020. PMID: 38279365. doi:10.1016/S2665-9913(20)30344-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。